Northwestern College Feinberg College of Drugs within the US has reported that outcomes from STEP 1 scientific trial of type-2 diabetes drug semaglutide (Ozempic) as soon as weekly was linked to a sustained, clinically related discount in physique weight in overweight grownup individuals.
The double-blind trial is funded by Novo Nordisk, which producers Rybelsus and Ozempic (semaglutides for treating diabetes).
It had 1,961 topics with a body-mass index (BMI) of 30 or above with out diabetes. They have been randomised right into a 2:1 ratio to obtain a once-weekly subcutaneous injection of semaglutide 2.4mg or placebo, together with life-style interventions, for 68 weeks.
The share change in physique weight and weight discount of at the least 5% have been the research’s co-primary endpoints.
In response to the outcomes, Semaglutide group confirmed a mean discount in physique weight from baseline of 14.9% versus 2.4% within the placebo group, indicating a remedy distinction of 12.4%.
Moreover, 86.4% of topics within the semaglutide group achieved weight reductions of 5% as in contrast with 31.5% within the placebo group, respectively.
Half of the topics receiving semaglutide achieved a weight discount of 15% or extra versus 4.9% within the placebo group.
Northwestern Drugs inner drugs doctor and Division of Endocrinology and of Medical Schooling Drugs professor Robert Kushner mentioned: “That is by far the best intervention we now have seen for weight administration whenever you examine it to most of the at the moment present medicine.
“Semaglutide units the bar for a brand new technology of simpler weight-loss medicines.”
As well as, topics receiving semaglutide had a better enchancment on cardiometabolic threat elements and a better betterment in bodily perform from baseline versus placebo.
Presently, oral semaglutide is marketed within the EU as Rybelsus for treating sort II diabetes as an adjunct to weight loss plan and train for adults with uncontrolled situation.
In September 2019, Novo Nordisk reported positive results from the Phase IIIa PIONEER clinical trial programme of oral semaglutide to deal with sort 2 diabetes sufferers.
Final December, the corporate sought approval for the once-weekly semaglutide for weight administration from the US Meals and Drug Administration (FDA) and European Medicines Company (EMA).